ResMed Continues to Rise after Phase 2 Study of CAT-HF
ResMed (RMD) is another mid-cap stock within the iShares U.S. Medical Devices ETF (IHI) that outperformed with a return of 0.9%.
Allergan (AGN) reported a rise of 48% in its revenue to ~$3.8 billion in 1Q16. The company reported a net profit of $1.2 billion in 1Q16.
Allergan’s (AGN) Anda distribution segment distributes generic pharmaceutical products, vaccines, and over-the-counter products in the US markets.
Allergan’s (AGN) international brands segment includes revenues from both branded and aesthetics products outside of the US markets.
Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.
Allergan (AGN) has classified its business into four segments. The company’s US brands segment is its largest revenue contributor.
Allergan (AGN) reported revenue of $3.8 billion in its 1Q16 results. This indicates over 48% revenue growth in 1Q16 compared to $2.6 billion in 1Q15.
Allergan reported revenue of $3.8 billion in 1Q16, a 48% rise over 1Q15. The company has leading global brands in its product portfolio.
Allergan’s new industry model, “growth pharma,” is based on identifying five characteristics that boost company growth and differentiate it from its peers.
On May 26, 2016, Allergan (AGN) was trading at a forward PE (price-to-earnings) multiple of ~14.7x compared to the industry average of 15.6x.
Boston Scientific (BSX) was the biggest gainer among the large caps of the iShares U.S. Medical Devices ETF (IHI).
Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.
Sarepta Therapeutics (SRPT) was the top performer within the SPDR S&P Biotech ETF (XBI) on May 25, 2016. It rose by 26.6%.
On May 31, 2016, Medtronic (MDT) will announce its 4Q16 earnings for the period ending April 30, 2016.
Medtronic (MDT) has managed to meet or exceed analysts’ earnings estimates for the last several quarters.
Due to Medtronic’s strong fundamentals, the company’s valuation multiple has witnessed a gradual rise since its 3Q16 earnings release.
In a Bloomberg survey of 26 brokerage companies on May 26, 2016, about 81% of analysts rated Medtronic as a “buy,” and 19% rated it as a “hold.”
Bristol-Myers Squibb reported an increase of 8.7% in revenues to ~$4.4 billion in 1Q16. But it reported a net profit of only about $1.2 billion in 1Q16.
Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.
Bristol-Myers Squibb’s (BMY) Cardiovascular segment includes the key drug Eliquis. The segment contributed nearly 16.7% of total revenues for 1Q16.